Published in Influenza Other Respir Viruses on November 19, 2010
Annual vaccination against influenza virus hampers development of virus-specific CD8⁺ T cell immunity in children. J Virol (2011) 1.16
Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol (2013) 1.10
An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respir Viruses (2012) 1.03
Local response to microneedle-based influenza immunization in the skin. MBio (2012) 1.03
Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis (2012) 1.03
Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One (2012) 1.00
Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine (2012) 0.99
Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses. Vaccine (2012) 0.96
Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus. PLoS One (2013) 0.96
Estimating the influenza vaccine effectiveness against medically attended influenza in clinical settings: a hospital-based case-control study with a rapid diagnostic test in Japan. PLoS One (2013) 0.94
Live attenuated and inactivated influenza vaccines in children. J Infect Dis (2014) 0.92
Increase in IFNγ(-)IL-2(+) cells in recent human CD4 T cell responses to 2009 pandemic H1N1 influenza. PLoS One (2013) 0.91
Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health (2016) 0.87
The receptor binding specificity of the live attenuated influenza H2 and H6 vaccine viruses contributes to vaccine immunogenicity and protection in ferrets. J Virol (2011) 0.86
Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination. J Infect Dis (2014) 0.86
Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production. J Virol Methods (2013) 0.86
Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic A/H1N1 viruses. PLoS One (2012) 0.86
Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Hum Vaccin Immunother (2013) 0.86
H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers. Hum Vaccin Immunother (2015) 0.84
Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines. PLoS One (2014) 0.83
Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines. J Infect Dis (2014) 0.82
Influenza vaccines: unmet needs and recent developments. Infect Chemother (2013) 0.81
Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype. Front Immunol (2015) 0.79
Prospects of HA-based universal influenza vaccine. Biomed Res Int (2015) 0.79
Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus. J Virol (2016) 0.78
Inactivated influenza virus vaccines: the future of TIV and QIV. Curr Opin Virol (2017) 0.77
Prevention of influenza in healthy children. Expert Rev Anti Infect Ther (2012) 0.77
A promoter mutation in the haemagglutinin segment of influenza A virus generates an effective candidate live attenuated vaccine. Influenza Other Respir Viruses (2014) 0.77
Neighborhood Influences on Seasonal Influenza Vaccination among Older African Americans in Atlanta, Georgia. J Immunol Tech Infect Dis (2016) 0.76
Olfactory bulb and hypothalamic acute-phase responses to influenza virus: effects of immunization. Neuroimmunomodulation (2013) 0.76
Administration time between seasonal live-attenuated influenza vaccine and trivalent influenza vaccine during the "Stop Flu at School" Campaign--Hawaii, 2009. Public Health Rep (2014) 0.75
Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine. Am J Prev Med (2016) 0.75
Seroprotective antibodies to 2011 variant influenza A(H3N2v) and seasonal influenza A(H3N2) among three age groups of US Department of Defense service members. PLoS One (2015) 0.75
Balancing the Efficacy and Safety of Vaccines in the Elderly. Open Longev Sci (2012) 0.75
Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza Vaccine. Front Immunol (2016) 0.75
A Single Mutation at PB1 Residue 319 Dramatically Increases the Safety of PR8 Live Attenuated Influenza Vaccine in a Murine Model without Compromising Vaccine Efficacy. J Virol (2015) 0.75
Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) in Adults. Clin Vaccine Immunol (2016) 0.75
Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA (2000) 8.31
Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med (2007) 6.54
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep (2009) 5.80
The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA (1994) 5.29
Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med (2006) 4.50
Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol (2004) 3.81
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA (1999) 3.53
Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med (2009) 3.49
Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev (2008) 2.69
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis (1994) 2.52
Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J (2006) 1.98
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J (2006) 1.94
Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel. JAMA (2009) 1.74
Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine (2009) 1.70
Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis (2008) 1.58
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis (2010) 1.53
Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J (2004) 1.52
Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine (2008) 1.52
Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Vaccine (2008) 1.45
Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics (2007) 1.28
Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med (1992) 1.21
Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine (2007) 1.19
Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine (2009) 1.19
Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. Influenza Other Respir Viruses (2010) 1.11
Influenza vaccine in healthy children: a meta-analysis. Vaccine (2005) 0.99
Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine (2003) 0.97
Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest (2006) 0.92
A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine (2011) 0.91
Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine. Vaccine (2010) 0.80
Recommendations for the management of herpes zoster. Clin Infect Dis (2007) 4.33
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med (2015) 4.23
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 3.86
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med (2012) 2.77
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med (2010) 2.73
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol (2010) 2.63
Validation of a 3-factor scoring model for the Pittsburgh sleep quality index in older adults. Sleep (2006) 2.62
Dose-related effects of smallpox vaccine. N Engl J Med (2002) 2.55
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin (2009) 2.51
The immunogenetics of smallpox vaccination. J Infect Dis (2007) 2.23
Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain (2004) 2.15
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother (2012) 2.11
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain (2007) 2.08
Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine (2007) 2.01
Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2012) 1.98
Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol (2010) 1.96
Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev (2003) 1.95
The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ (2010) 1.88
Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. J Infect Dis (2005) 1.84
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81
Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc (2010) 1.76
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin (2011) 1.73
Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis (2011) 1.71
DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis (2007) 1.71
Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis (2008) 1.70
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2013) 1.69
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine (2007) 1.68
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol (2003) 1.63
The prevention and management of herpes zoster. Med J Aust (2008) 1.60
Response to smallpox vaccine in persons immunized in the distant past. JAMA (2003) 1.59
Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis (2007) 1.56
Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J (2004) 1.52
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin (2011) 1.46
Hepatitis C prevalence in children with perinatal human immunodeficiency virus infection enrolled in a long-term follow-up protocol. Arch Pediatr Adolesc Med (2004) 1.44
Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis (2004) 1.42
A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol (2009) 1.42
Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry (2008) 1.38
Comparison of results of detection of rhinovirus by PCR and viral culture in human nasal wash specimens from subjects with and without clinical symptoms of respiratory illness. J Clin Microbiol (2007) 1.34
Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J (2006) 1.32
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J (2003) 1.32
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis (2010) 1.30
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat Commun (2010) 1.29
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Vaccine (2008) 1.25
A prospective study of the herpes zoster severity of illness. Clin J Pain (2010) 1.22
Evaluation of smallpox vaccines using variola neutralization. J Gen Virol (2009) 1.21
Implications of the emergence of a novel H1 influenza virus. N Engl J Med (2009) 1.20
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis (2004) 1.20
Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J Virol (2005) 1.19
VZV T cell-mediated immunity. Curr Top Microbiol Immunol (2010) 1.17
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine (2010) 1.17
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 1.16
Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis (2010) 1.14
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One (2009) 1.10
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis (2013) 1.09
Nectin-1/HveC Mediates herpes simplex virus type 1 entry into primary human sensory neurons and fibroblasts. J Neurovirol (2005) 1.08
A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J (2009) 1.06
Human sensory neurons derived from induced pluripotent stem cells support varicella-zoster virus infection. PLoS One (2012) 1.05
Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine (2012) 1.05
Poxvirus zoonoses--putting pocks into context. N Engl J Med (2004) 1.05
Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine (2010) 1.04
Varicella vaccine in the United States: a decade of prevention and the way forward. J Infect Dis (2008) 1.02
Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J (2012) 1.01
Impairments in health functioning and sleep quality in older adults with a history of depression. J Am Geriatr Soc (2006) 1.01
Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Pediatrics (2007) 1.00
Antibody responses to vaccinia membrane proteins after smallpox vaccination. J Infect Dis (2007) 0.99
Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci Transl Med (2013) 0.99
Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine. Vaccine (2009) 0.98
Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2009) 0.97
The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J (2010) 0.97
Major depressive disorder and immunity to varicella-zoster virus in the elderly. Brain Behav Immun (2011) 0.96
Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob Agents Chemother (2002) 0.96
Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis (2005) 0.95
Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine (2007) 0.95
Persistent sleep disturbance: a risk factor for recurrent depression in community-dwelling older adults. Sleep (2013) 0.94
Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy. Vaccine (2013) 0.89
Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia. Clin Infect Dis (2007) 0.89
Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2010) 0.89
Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis (2013) 0.89
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario. Vaccine (2013) 0.89
Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine (2011) 0.88
Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines. Clin Vaccine Immunol (2012) 0.88
Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother (2013) 0.87
Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis (2004) 0.87
Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis (2013) 0.87
Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis (2012) 0.87
Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine (2005) 0.86
Postentry events are responsible for restriction of productive varicella-zoster virus infection in Chinese hamster ovary cells. J Virol (2006) 0.86
Fractionation of neurons and satellite cells from human sensory ganglia in order to study herpesvirus latency. J Virol Methods (2002) 0.86
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study. Hum Vaccin Immunother (2014) 0.86
A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. PLoS One (2011) 0.85
Resistance to antiretrovirals in HIV-infected pregnant women. J Clin Virol (2009) 0.85
Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol (2011) 0.82